目的 探析金水寶片聯(lián)合達(dá)格列凈治療糖尿病腎病的效果。方法 收集2022年1月—2024年2月在中國人民解放軍聯(lián)勤保障部隊(duì)第九〇四醫(yī)院接受治療的102例糖尿病腎病患者資料，按治療方式將患者分為對照組和治療組，每組各51例。對照組患者口服達(dá)格列凈片，1片/次，1次/d；治療組患者在對照組基礎(chǔ)上口服金水寶片，4片/次，3次/d。兩組均連續(xù)治療12周。比較兩組臨床療效、血糖指標(biāo)、血管內(nèi)皮指標(biāo)和腎功能指標(biāo)。結(jié)果 治療組的總有效率96.08%高于對照組的總有效率84.31%（P＜0.05）。與治療前相比，兩組空腹血糖、糖化血紅蛋白（HbA1c）均降低（P＜0.05），且治療組各血糖指標(biāo)水平較對照組均更低（P＜0.05）。與治療前相比，兩組患者血清一氧化氮（NO）水平升高，血清內(nèi)皮素-1（ET-1）水平降低（P＜0.05），且治療組較對照組血清NO水平更高，血清ET-1水平更低（P＜0.05）。與治療前相比，兩組患者血清血肌酐（Scr）、血尿素氮（BUN）均降低（P＜0.05），且治療組腎功能指標(biāo)水平較對照組更低（P＜0.05）。結(jié)論 金水寶片聯(lián)合達(dá)格列凈治療糖尿病腎病可控制患者血糖，改善腎功能，保護(hù)血管內(nèi)皮功能。

Objective To explore the effect of Jinshuibao Tablets combined with dapagliflozin in treatment of diabetes nephropathy. Methods The data of 102 patients with diabetes nephropathy who were treated in the 94th Hospital of the Joint Logistic Support Force of PLA from January 2022 to February 2024 were collected. The patients were divided into control and treatment group according to the treatment mode, with 51cases in each group. The control group patients took Dapagliflozin tablets orally, 1 tablets/time, once daily. On the basis of the control group, the treatment group took Jinshuibao Tablets orally, 4 tablets/time, 3 times daily. Both groups were treated continuously for 12 weeks. The clinical efficacy, blood glucose indicators, vascular endothelial indicators, and renal function indicators between two groups were compared. Results The total effective rate (96.08%) of the treatment group was higher than 84.31% of the control group (P < 0.05). After treatment, fasting blood glucose and HbA1c levels in two groups were decreased (P < 0.05), and the various blood glucose indicators levels in the treatment group were lower than those in the control group (P < 0.05). Compared with before treatment, both groups showed an increase in serum NO and a decrease in serum ET-1 levels (P < 0.05). And the treatment group had higher serum NO levels and lower serum ET-1 levels than those in the control group (P < 0.05). The serum levels of Scr and BUN in both groups were decreased after treatment (P < 0.05), and the serum levels of Scr and BUN in the treatment group were lower than those in the control group (P < 0.05). Conclusion Jinshuibao Tablets combined with dapagliflozin is effective in treatment of diabetes nephropathy, and can control blood sugar, improve renal function and protect vascular endothelial function.

R977

蘇州市“科教興衛(wèi)”青年科技項(xiàng)目（KJXW2022086）